Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/1999

01-07-1999

Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor‐1 in human breast cancer cell lines

Authors: Dan Tong, Klaus Czerwenka, Jan Sedlak, Christian Schneeberger, Ingrid Schiebel, Nicole Concin, Sepp Leodolter, Robert Zeillinger

Published in: Breast Cancer Research and Treatment | Issue 1/1999

Login to get access
Metadata
Title
Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor‐1 in human breast cancer cell lines
Authors
Dan Tong
Klaus Czerwenka
Jan Sedlak
Christian Schneeberger
Ingrid Schiebel
Nicole Concin
Sepp Leodolter
Robert Zeillinger
Publication date
01-07-1999
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 1/1999
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1006262501062

Other articles of this Issue 1/1999

Breast Cancer Research and Treatment 1/1999 Go to the issue

OriginalPaper

Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients

OriginalPaper

Quality of life in the first year after breast cancer surgery: rehabilitation needs and patterns of recovery

OriginalPaper

Schedule‐dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro

OriginalPaper

Hypermethylation of the Wilms' tumor suppressor gene CpG island in human breast carcinomas

OriginalPaper

Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer

OriginalPaper

Rural breast cancer treatment: evidence from the Reaching Communities for Cancer Care (REACH) project
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits